Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships

By The Science Advisory Board staff writers

September 10, 2020 -- Ginkgo Bioworks and artificial intelligence (AI) drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus and develop associated therapeutics.

The partnership will utilize Ginkgo's bioengineering platform to express and screen thousands of SARS-CoV-2 antibody candidates. It will also adapt and scale Totient's tertiary lymphoid structures (TLSs), which were designed for oncology and autoimmunity solutions.

The TLS platform will reconstruct antibodies from bronchoalveolar lavage fluid samples of patients with COVID-19 at Avera McKennan Hospital in South Dakota. Gingko and Totient hope to identify at least one patient-derived neutralizing antibody to advance into further studies, with the ultimate goal of developing a high-affinity therapeutic.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.